share_log

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Patel Naimish

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Patel Naimish

CRISPR Therapeutics | 3:首次持股声明-高管 Patel Naimish
美股sec公告 ·  05/28 22:31
Moomoo AI 已提取核心信息
CRISPR Therapeutics AG, represented by Naimish Patel, the company's Chief Medical Officer, has filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 28, 2024. The Form 3 filing indicates that Patel does not beneficially own any non-derivative or derivative securities of CRISPR Therapeutics. This standard disclosure is required under Section 16(a) of the Securities Exchange Act of 1934 and is a routine filing for officers of publicly traded companies to report securities holdings and transactions to the SEC.
CRISPR Therapeutics AG, represented by Naimish Patel, the company's Chief Medical Officer, has filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 28, 2024. The Form 3 filing indicates that Patel does not beneficially own any non-derivative or derivative securities of CRISPR Therapeutics. This standard disclosure is required under Section 16(a) of the Securities Exchange Act of 1934 and is a routine filing for officers of publicly traded companies to report securities holdings and transactions to the SEC.
由该公司首席医疗官奈米什·帕特尔代表的CRISPR Therapeutics AG已于2024年5月28日向美国证券交易委员会提交了初步的证券实益所有权声明。表格3文件表明,帕特尔不以实益方式拥有CRISPR Therapeutics的任何非衍生或衍生证券。该标准披露是1934年《证券交易法》第16(a)条所要求的,是上市公司高管向美国证券交易委员会报告证券持有和交易的例行文件。
由该公司首席医疗官奈米什·帕特尔代表的CRISPR Therapeutics AG已于2024年5月28日向美国证券交易委员会提交了初步的证券实益所有权声明。表格3文件表明,帕特尔不以实益方式拥有CRISPR Therapeutics的任何非衍生或衍生证券。该标准披露是1934年《证券交易法》第16(a)条所要求的,是上市公司高管向美国证券交易委员会报告证券持有和交易的例行文件。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息